Stock-Based Compensation | 9. Stock-Based Compensation Equity Incentive Plans In May 2017, our Board of Directors adopted, and our stockholders approved, the 2017 Equity Incentive Plan (the “2017 Plan”), which became effective as of the date of the final prospectus for our initial public offering. The 2017 Plan provides for the grant of incentive stock options to employees and for the grant of nonstatutory stock options, restricted stock awards, RSUs, stock appreciation rights, performance-based stock awards, and other forms of equity compensation to employees, including officers, non-employee directors, and consultants. We initially reserved 6,421,442 shares of Class A common stock for issuance under the 2017 Plan, which included 421,442 shares that remained available for issuance under our 2007 Stock Option Plan (the “2007 Plan”) at the time the 2017 Plan became effective. The number of shares reserved under the 2017 Plan increases for any shares subject to outstanding awards originally granted under the 2007 Plan that expire or are forfeited prior to exercise. As a result of the adoption of the 2017 Plan, no further grants may be made under the 2007 Plan. As of June 30, 2021, there were 7,175,469 shares of Class A common stock reserved for issuance under the 2017 Plan, of which 4,223,260 were available to be issued. Stock Options We estimate the fair value of stock options containing only a service condition using the Black-Scholes option pricing model, which requires the use of subjective assumptions, including the expected term of the option, the current price of the underlying stock, the expected stock price volatility, expected dividend yield, and the risk-free interest rate for the expected term of the option. The expected term represents the period of time the stock options are expected to be outstanding. Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected term of the stock options, we use the simplified method to estimate the expected term for our stock options. Under the simplified method, the expected term of an option is presumed to be the mid-point between the vesting date and the end of the contractual term. Expected volatility is based on historical volatilities for publicly traded stock of comparable companies over the estimated expected term of the stock options. We assume no dividend yield because dividends are not expected to be paid in the near future, which is consistent with our history of not paying dividends. In May 2019, our Board of Directors granted a stock option to purchase 700,000 shares of our Class A common stock to our Chief Executive Officer (the "2019 CEO Grant") under the 2017 Plan with an exercise price of $33.98 per share. The 2019 CEO Grant is eligible to vest based on the achievement of a stock price appreciation target of our Class A common stock. Specifically, the 2019 CEO Grant vests when shares of our Class A common stock close at or above $84.63 per share for a period equal to or greater than 90 consecutive calendar days or upon the occurrence of a change in control in which the value of our Class A common stock is equal to or greater than $84.63 per share within five years of the grant date. The fair value of the 2019 CEO Grant was determined using a Monte Carlo simulation. The fair value of the award at the grant date was $9.5 million and is amortized over the derived service period of 2.6 years. Effective February 2021, the 2019 CEO Grant has satisfied all of the conditions required to be considered fully vested. As a result, we accelerated the recognition of approximately $3.3 million in stock-based compensation expense in the six months ended June 30, 2021. The following table summarizes stock option activity for the six months ended June 30, 2021: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2021 3,399,240 $ 14.06 4.9 $ 503,174 Granted — — — — Exercised (299,920) 6.94 — 33,230 Expired — — — — Forfeited (10,060) 11.62 — — Outstanding at June 30, 2021 3,089,260 $ 14.76 4.4 $ 379,935 Exercisable at June 30, 2021 2,850,280 $ 15.04 4.3 $ 349,747 There were no stock options granted during the six months ended June 30, 2021 and 2020. The total fair value of stock options that vested during the six months ended June 30, 2021 and 2020 was $10.5 million and $1.0 million, respectively. As of June 30, 2021, the total compensation cost related to unvested stock options not yet recognized was $0.2 million, which will be recognized over a weighted average period of 0.8 years. Restricted Stock Units The following table summarizes RSU activity for the six months ended June 30, 2021: Number of Shares Weighted Average Grant Date Fair Value Non-vested and outstanding at January 1, 2021 1,165,003 $ 46.04 Granted 110,008 139.17 Vested (99,350) 46.44 Forfeited (48,965) 63.20 Non-vested and outstanding at June 30, 2021 1,126,696 54.35 As of June 30, 2021, total unrecognized compensation cost related to unvested RSUs was appro ximately $51.8 million, which will be recognized over a weighted average period of 2.2 years. The following table summarizes the components of our stock-based compensation expense by instrument type for the three and six months ended June 30, 2021 and 2020 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 RSUs $ 4,403 $ 2,475 $ 8,408 $ 4,774 Stock options 40 1,047 3,773 2,131 Common stock awards to Board of Directors 155 92 311 185 Total stock-based compensation expense $ 4,598 $ 3,614 $ 12,492 $ 7,090 Stock-based compensation expense for RSUs, stock options, and issuances of common stock to the Board of Directors is included in the following line items in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2021 and 2020 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of revenue Subscriptions $ 295 $ 229 $ 592 $ 442 Professional services 865 317 1,506 529 Operating expenses Sales and marketing 1,197 657 2,305 1,410 Research and development 1,069 619 2,084 1,172 General and administrative 1,172 1,792 6,005 3,537 Total stock-based compensation expense $ 4,598 $ 3,614 $ 12,492 $ 7,090 |